LUMINARA
a Phase 2b, two cohort, randomised, double blind, placebo controlled, multicentre, dose-ranging study of AZD5462 in stable patients with chronic heart failure
- Stage
- followup
- Medicine
- AZD5462
- Population
- Hartfalen
- Phase
- IIb
- First Patient In
- 15 August 2024
- Last Patient In
- 11 July 2025
- Last Patient Last Visit
- 16 February 2026
National Lead
dr. J. Schaap
Cardioloog
Study Director